Phase 2 Study of Amrubicin for patients with recurrent advanced squamous cell lung cancer after first line treatment. - Phase 2 Study of Amrubicin for patients with recurrent advanced squamous cell lung cancer after first line treatment.

Kansai Medical University Hirakata Hospital0 个研究点目标入组 40 人开始时间: 2011年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Uncontrolled infection or Serious medical complications 2)Massive pleural effusion or ascites after drainage and controrable pleural effusion for 2 weeks accept controrable pleural effusion with OK-432 3)current or previous treated brain metastasis 4)severe cardiac disease 5)uncontrolled diabetes mellitus 6)receiving anticoagulant drug(except Aspirin under 325mg/day) 7)uncontrolled hypertension 8)current or previous (within the last 1 year) history of GI perforation 9)interstitial pneumonia or lung fibrosis evident on CT 10)history of drug induced interstitial pneumonia 11)patient who has been scheduling operation for examination period 12)treatment history of Amurubicin 13)severe drug allergy 14)active concomitant malignancy 15)severe psychological disease 16)pregnant or lactating women or those who declined contraception 17)those judged to be not suitable by the attending physician

发起方

Kansai Medical University Hirakata Hospital